At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
To Compare the Efficacy of (Rifaximin + Mebeverine), (Rifaximin + Amitriptyline), and (Rifaximin + Psyllium Husk) in Irritable Bowel Syndrome Associated With Diarrhea
In Brief
A Phase 4 clinical trial evaluating Rifaximin 550 MG, Mebeverine 135 MG, and 2 other interventions for Irritable Bowel Syndrome With Diarrhea. Completed, enrolled 162 participants across 1 site.
Detailed Summary
The goal of this clinical trial is to compare the efficacy of four different drugs in combination for management of irritable bowel syndrome (IBS)-associated diarrhea. The main question to answer is: * Is there a significant difference in effect of different drug combinations in management of irritable bowel syndrome with diarrhea? Participants will be divided into 3 treatment groups. * Each group will be given a combination of drugs for 2 weeks * At the end of study, efficacy of different drug combinations and their potential side effects will be compared between the treatment groups
Study Details
Timeline
Interventions
Rifaximin 550 MG Oral Thrice Daily for 2 weeks will be included in all three treatment regimes i.e A, B and C
Mebeverine 135 MG Oral Twice Daily for 2 weeks will be included in Group A Treatment Regimes
Psyllium Husk 15-35 MG Oral Once Daily for 2 weeks will be included in Group C Treatment Regimes
Amitriptyline Hydrochloride 25 MG Oral Once Daily for 2 weeks will be included in Group B Treatment Regimes